Positive Opinions in Europe For J&J's Zytiga And Telaprevir, Pfizer's Tafamidis And Orion's Dexmedetomidine
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson's Zytiga and telaprevir, as well as the first drug from Pfizer's rare disease unit and a new sedative from Swedish company Orion, were among the products granted approval by Europe's scientific advisory panel at its July meeting.
You may also be interested in...
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.